IQVIA™ Real-World Insights Bibliography

Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case-Control Study
Author(s): Farah Toron 1, Maureen P Neary 2, Timothy W Smith 3, David Gruben 4, William Romero 5, Amy Cha 3, Keyur Patel 1, Simona Z Vasileva 6, Mahreen Ameen 7
Affiliations(s): 1Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. 2Inflammation & Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA. 3Inflammation & Immunology, Pfizer Inc, New York, New York, USA. 4Global Biometrics and Data Management (Statistics), Pfizer Inc, Groton, Connecticut, USA. 5Inflammation & Immunology, Pfizer Ltd, Surrey, UK. 6Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. simona.vasileva@iqvia.com. 7Royal Free London National Health Services Foundation Trust, London, UK.
Publication(s):  PMID: 33846907 PMCID: PMC8163940 DOI: 10.1007/s13555-021-00519-7
Document Type(s): Article,
Countries: UK,
Click here for the abstract
C:
Y:
Dermatology, Drug Utlization Study, Methodology,
2021
  L:
A:
English
direct to patient research, direct-to-patient research, Economic evaluation, Population Based Study, Retrospective database analysis,
  Add to report
 
 
DERMATOLOGY AS AN EXAMPLE Originator and Generic Market Access Pretection Strategies in Germany Using Dermatology as an Example
Author(s): Greiner RA, Antoni B, Batscheider A, Bonduelle D Roxlau T, Stratil AS
Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany
Publication(s): 
Document Type(s): Abstract,
Countries: Germany,
C:
Y:
Dermatology, Health economics,
2018
  L:
A:
English
Market impact,
  Add to report
 
 
Cost-Effectiveness Analysis of Brodalumab in Moderate-to-Severe Plaque Psoriasis in Canada
Author(s): Xue, W. 1, Gray, E. 1, Khoudigian-Sinani, S. 2, Barbeau, M. 3, Frieder, D. 3
Affiliations(s): 1 IQVIA, London, UK, 2 IQVIA Mississauga, ON, Canada, 3 Valeant Canada LP, Laval QC, Canada
Publication(s):  ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD, USA
Document Type(s): Poster,
Countries: Canada,
Click here for the abstract
C:
Y:
Dermatology,
2018
  L:
A:
English
Database Study,
  Add to report
 
 
Efficacy of Brodalumab in the Treatment of Moderate-to-Severe Psoriasis: A Network Meta-Analysis
Author(s): Xue, W. 1, Saharia, P. 2, Gray, E. 1, Khoudigian-Sinani, S. 3, Barbeau, M. 4, Frieder, D. 4
Affiliations(s): 1. IQVIA, London, UK, 2. IQVIA Gurugram, India, 3. IQVIA Mississauga, ON, Canada, 4. Valeant Canada LP, Laval QC, Canada
Publication(s): 
Document Type(s): Poster,
Countries: Canada,
Click here for the abstract
C:
Y:
Dermatology,
2018
  L:
A:
English
Meta analysis,
  Add to report
 
 
Treatment Patterns, Adherence, and Persistence among Psoriasis Patients Treated with Biologics in a Real-World Setting, Overall and by Disease Severity
Author(s): Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, Merola JF, Zbrozek A, Araujo AB
Affiliations(s): Murage MJ: Eli Lilly and Company; Anderson A: IQVIA; Oliveria SA: IQVIA; Casso D: IQVIA; Ojeh CK: Eli Lilly and Company; Muram TM: Eli Lilly and Company; Merola JF: cBrigham and Women?s
Publication(s):  Journal of Dermatological Treatment
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Dermatology, Drug Utlization Study, Patient Registries & Real-World Study Methods,
2018
  L:
A:
English
Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis,
  Add to report
 
 
Healthcare Resource Utilization and Costs among Psoriasis Patients Treated with Biologics, Overall and by Disease Severity
Author(s): Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, Merola JF, Araujo AB
Affiliations(s): Murage MJ: Eli Lilly and Company; Anderson A: IQVIA; Oliveria SA: IQVIA; Casso D: IQVIA; Ojeh CK: Eli Lilly and Company; Muram TM: Eli Lilly and Company; Merola JF: Harvard Medical School; Araujo AB: Eli Lilly and Company
Publication(s):  Journal of Medical Economics
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Dermatology, Patient Registries & Real-World Study Methods, Pricing and reimbursement,
2018
  L:
A:
English
Cost analysis, Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis,
  Add to report
 
 
Adherence and Persistence to Biologics Among Psoriasis Patients, Overall and by Disease Severity
Author(s): Murage MJ, Anderson A, Oliveria SA, Al Sawah S, Casso D, Malatestinic WN, Tanaka Y, Muram TM, Ojeh CK, Zbrozek A, Araujo AB
Affiliations(s): Murage MJ: Eli Lilly and Company; Anderson A: IQVIA; Oliveria SA: IQVIA; Al Sawah S: Eli Lilly and Company; Casso D: IQVIA; Malatestinic WN: Eli Lilly and Company; Tanaka Y: Eli Lilly and Company; Muram TM: Eli Lilly and Company; Ojeh CK: Eli Lilly and Company; Zbrozek A: Eli Lilly and Company, Araujo AB: Eli Lilly and Company
Publication(s):  34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Document Type(s): Abstract,
Countries: USA,
C:
Y:
Database Validity and methodology, Dermatology, Drug Utlization Study, Urology,
2018
  L:
A:
English
Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis,
  Add to report
 
 
Healthcare Resource Utilization and Costs Among Psoriasis Patients Treated with Biologics, Overall and by Disease Severity
Author(s): Al Sawah S, Anderson A, Casso D, Murage MJ, Oliveria SA, Malatestinic WN, Tanaka Y, Muram TM, Ojeh CK, Zbrozek A, Araujo AB
Affiliations(s): Al Sawah S: Eli Lilly and Company; Anderson A: IQVIA; Casso D: IQVIA; Murage MJ: Eli Lilly and Company; Oliveria SA: IQVIA; Malatestinic WN: Eli Lilly and Company; Tanaka Y: Eli Lilly and Company; Muram TM, Ojeh CK: Eli Lilly and Company; Zbrozek A, Araujo AB: Eli Lilly and Company
Publication(s):  34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Document Type(s): Abstract,
Countries: USA,
C:
Y:
Dermatology, Drug Utlization Study, Patient Registries & Real-World Study Methods,
2018
  L:
A:
English
Database Study, Epidemiological study, Retrospective database analysis,
  Add to report
 
 
Epidemiologic and economic burden of HPV-related diseases in Spain: Potential benefit of adding 5 additional types in the nonavalent vaccine.
Author(s): López N1, Torné A2, Franco A3, San-Martin M1, Viayna E4, Barrull C4, Perulero N4
Affiliations(s): 1 Medical Affairs, Sanofi Pasteur MSD, Madrid, Spain 2 Gynecologic Oncology Unit, Institut Clinic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clínic-Institut d′Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine, University of Barcelona, Barcelona, Spain 3 Diagnostic Unit of Urology, Clinic Institute of Nephrology and Urology (ICNU) Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain 4 Health Economics and Outcomes Research, IMS Health, Barcelona, Spain
Publication(s):  HPV2017 31st International papillomavirus conference, 2017, February 28 ? March 4, Cape Town, South Africa
Document Type(s): Poster,
Countries: Spain,
Click here for the abstract
C:
Y:
Dermatology, Health economics, Immunology and Vaccination, Oncology,
2017
  L:
A:
English
Burden of illness, Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Literature Review, Survey research,
  Add to report
 
 
Impacto económico de las enfermedades asociadas al VPH en España: beneficio potencial de la vacuna nonavalente frente a la tetravalente [Economic impact of HPV-associated diseases in Spain: potential benefit of nonvalorent versus tetravalent vaccine].
Author(s): López N1, Torné A2, Franco A3, San-Martin M1, Viayna E4, Barrull C4
Affiliations(s): 1 Medical Affairs, MSD, Madrid, Spain 2 Gynecologic Oncology Unit, Institut Clinic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clínic-Institut d′Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine, University of Barcelona, Barcelona, Spain 3 Diagnostic Unit of Urology, Clinic Institute of Nephrology and Urology (ICNU) Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain 4 Health Economics and Outcomes Research, IMS Health, Barcelona, Spain
Publication(s):  XXXVII Jornadas de Economía de la Salud, 2017, 6 - 8 de septiembre, Barcelona, España
Document Type(s): Poster,
Countries: Spain,
Click here for the abstract
C:
Y:
Dermatology, Health economics, Immunology and Vaccination, Oncology,
2017
  L:
A:
Spanish
Burden of illness, Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Literature Review, Survey research,
  Add to report
 
 
 1 of 11 Next Page Last Page